Pazopanib API
CAS.NO:444731-52-6
structural formula:C21H23N7O2S
EINECS.no:251-228-4
Other names:Pazopanib free base;Pezopanil Hcl;CS-1857;GW786034;Votrient
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted Pazopanib API Manufacturer & Supplier
Pazopanib API powder is a new angiogenesis inhibitor that can interfere with the angiogenesis required for the survival and growth of stubborn tumors. It targets the vascular endothelial growth factor receptor (VEGFR) and works by inhibiting the angiogenesis that supplies blood to tumors. Pazopanib free base provided by Xi'an Faithful BioTech Co., Ltd. can not only treat advanced renal cell carcinoma, soft tissue sarcoma (STS), epithelial ovarian cancer, non-small cell lung cancer (NSCLC) and many other similar diseases, especially for thyroid cancer. It can not only stabilize the disease for a long time, but also maintain the effect for a long time, making the tumor volume shrink continuously. Therefore, it is called the savior of thyroid cancer by the medical community.
Pazopanib API Introduction
Pazopanib API material, as a novel multi-target tyrosine kinase inhibitor, has a mechanism of action that is very similar to the well-known sorafenib and sunitinib. It can also inhibit and even block multiple targets related to angiogenesis, such as VEGFR-1, VEGFR-2, and VEGFR-3, PDGFR - α, PDGFR - β that regulate angiogenesis and the proliferation of certain tumor cells, and c-Kit intracellular tyrosine kinase that regulates cell proliferation and survival.
Animal studies have found that in vitro, pazopanib inhibits ligand induced autophosphorylation of VEGFR-2, Kit, and PDGFR receptors. In vivo, pazopanib inhibits VEGF induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumors in transplanted tumors in mice.
Specifications
Item | Specifications | Results |
Appearance | White to off white crystalline powder | Complies |
Identification (H-NMR,LC-MC) | Conforms to Standard | Complies |
Purity (HPLC) | NLT 98% | 98.5% |
Melting Point | NLT 182℃ | 183 ℃ |
Bulk density | 0.2-0.5g/cm3 | Complies |
Heavy Metals | NMT10ppm | Negative |
Loss on drying | NLT 1% | 0.88% |
Residue on Ignition | NMT 0.5% | 0.10% |
Related substance | Single impurity≤0.2% Total impurities≤1.0% | 0.001% 0.1% |
Chlorides | ≤0.5% | 0.001% |
Total Plate Count | ≤ 1000 cfu/g | 11.23 cfu/g |
Yeast&Mold | ≤ 100 cfu/g | 0.48 cfu/g |
E.coil | Negative | Negative |
Salmonella | Negative | Negative |
| Conclusion | Conform with enterprise specification （USP 41）. |
Why Choose Us?
We focus on providing high-quality Pazopanib API powders with the following core advantages:
Firstly, a strict quality control system. Our production process follows international standards and undergoes multiple tests from raw material procurement to finished product delivery to ensure that each batch of products has high purity, minimal impurities, and meets pharmaceutical grade standards.
Secondly, a stable supply chain and fast delivery capability. We have a comprehensive production and warehousing system that can ensure long-term stable supply and flexibly adjust delivery times according to customer needs, supporting fast delivery worldwide.
Finally, professional technical support and services. We are equipped with an experienced technical team that can provide customers with process optimization suggestions, customized synthesis solutions, and comprehensive technical documentation support to assist customers in the smooth progress of research and production.
Choosing us means choosing Pazopanib free base raw powder that provides reliable quality and professional services.
Our email address is:sales8@faithfulbio.com, Welcome your letter.
Clinical application and adverse reactions
Pazopanib API powder was approved by the FDA on October 19, 2009 for the treatment of renal cell carcinoma, as well as for advanced soft tissue sarcoma (STS) patients who have previously received chemotherapy, platinum resistant or platinum refractory epithelial ovarian cancer, and maintenance therapy for non-small cell lung cancer (NSCLC) after first-line chemotherapy. Clinical trials have found that the most common adverse reactions (≥ 20%) are diarrhea, hypertension, changes in hair color (depigmentation), nausea, loss of appetite, and vomiting.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1: What is its therapeutic effect?
Clinical studies have shown significant efficacy in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. In patients with renal cell carcinoma, CS-1857 can inhibit angiogenesis, slow down tumor growth and spread, and significantly prolong the median duration of remission. GW786034 has a good therapeutic effect on malignant soft tissue tumors such as synovial sarcoma and rhabdomyosarcoma in patients with soft tissue sarcoma.
Q2: What are the basic parameters of GW786034 API?
Pazopanib free base raw material is a white or off white crystalline powder with the molecular formula C21H23N7O2S, molecular weight 437.52, and CAS number 444731-52-6. Purity ≥ 98% (HPLC), melting point 301-313 ℃, flash point 359 ℃, density 1.3. The storage condition is -20 ℃, sealed and protected from light, with a shelf life of 2 years.
Q3: What are the quality standards for Pezopanil Hcl raw materials?
The Pazopanib API must comply with international pharmacopoeia standards such as CP, USP, BP, EP, etc. The main quality indicators include: content ≥ 98% (calculated as dry product), related substances ≤ 1.0% (single impurities ≤ 0.5%), drying loss ≤ 1.0%, ignition residue ≤ 0.1%, and heavy metals ≤ 10ppm.
Contact us
Pazopanib API is a tyrosine kinase inhibitor (TKI) suitable for the treatment of advanced renal cell carcinoma patients. If you need a tyrosine kinase inhibitor as your research material, please leave us a message. My email is:sales8@faithfulbio.com . I will provide you with a good price according to the company's policy.
